Inhibitory Effect of Phenobarbital on the Development of Gliomas in WF Rats Treated Neonatally With N-Ethyl-N-nitrosourea

The present study was undertaken to evaluate the effect of phenobarbital (PB) on the development of neurogenic tumors induced in WF rats by neonatal administration of N-ethyl-N-nitrosourea (ENU; CAS: 759-73-9). Group I rats were given a single sc injection in the backs of 5 mg ENu/kg body weight wit...

Full description

Saved in:
Bibliographic Details
Published in:JNCI : Journal of the National Cancer Institute 1985-03, Vol.74 (3), p.725-728
Main Authors: Naito, Masashi, Aoyama, Hideyuki, Ito, Akihiro
Format: Article
Language:English
Subjects:
Animals
Biological and medical sciences
Carcinogenesis, carcinogens and anticarcinogens
Chemical agents
Dose-Response Relationship, Drug
Ethylnitrosourea
Female
Glioma - chemically induced
Glioma - prevention & control
Male
Medical sciences
Nitrosourea Compounds
Phenobarbital - blood
Phenobarbital - pharmacology
Rats
Rats, Inbred WF
Sex Factors
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The present study was undertaken to evaluate the effect of phenobarbital (PB) on the development of neurogenic tumors induced in WF rats by neonatal administration of N-ethyl-N-nitrosourea (ENU; CAS: 759-73-9). Group I rats were given a single sc injection in the backs of 5 mg ENu/kg body weight within 24 hours after birth. In group II, continuous oral administration of 0.05% PB in the drinking water was commenced 4 weeks after birth. Following neonatal injection of ENU, administration of PB was commenced 4 weeks after birth in group III. Rats in group IV served as untreated controls. All groups consisted of about an equal number of both sexes of rats. The experiment was terminated when the rats were 52 weeks old. The incidence of all neurogenic tumors in both sexes combined was 11 of 26 (42%) in group I and 3 of 22 (14%) in group III (P>.05). The incidence of gliomas alone was 10 of 26 (38%) in group I and 2 of 22 (9%) in group III (P.05), whereas in males, 3 of 13 (23%) in group I and 1 of 10 (10%) in group III (P>.05), the difference was not statistically significant. At the end of the experiment the mean serum level of PB in females (33.0 µg/ml) was significantly higher than that in males (19.8 µg/ml) (P
ISSN:0027-8874
1460-2105
DOI:10.1093/jnci/74.3.725